Infectious Disease

Community pharmacies deliver personalized travel medicine, helping travelers leave protected and prepared.

Following multiple exits in this role throughout President Trump’s second term, the new director’s tenure is reported to be permanent going forward.

This medication is the first FDA-approved OTC innovation in the cold and flu category in 14 years.

Centuries of vaccine science saved more lives than any other intervention, and pharmacists matter now more than ever.

New survey data reveal information gaps in respiratory syncytial virus immunization decisions.

Voluntary licensing agreements covering 129 low- and middle-income countries arrive as phase 3 trials continue.

Detailed results show the investigational islatravir/lenacapavir combination sustained virologic suppression as a potential once weekly HIV treatment.

A rapidly growing multistate cyclosporiasis outbreak has pushed national case counts to nearly 7000.

A newly published review traces chikungunya's re-emergence to a record 2025 outbreak in China, and 2 FDA-approved vaccines shape prevention strategy for pharmacists.

West Nile virus cases rise early in 2026, with Arizona leading with 32 cases.

Prior to the study, researchers report a significant lack of exploration regarding artificial intelligence's use in antimicrobial stewardship programs conducted in pharmacy practice.

The collaborative effort includes millions of dollars dedicated to cloud and artificial technology for a global antimicrobial resistance intelligence platform.

Updated charter shifts committee governance to the CDC director and drops fixed meeting schedules.

As cases approach the full-year 2025 total, declining vaccination coverage and vaccine hesitancy put pharmacists on the front lines of a public health crisis.

AAP challenges HHS as ACIP stalls, leaving pharmacists and health care in limbo on vaccine coverage and respiratory recommendations.

The first generic rifapentine expands affordable treatment for active and latent tuberculosis.

Retracted vaccine-autism study exposes statistical flaws, reigniting hepatitis B birth-dose debate and highlighting why pharmacists must rely on evidence-based data.

FDA clears first generic Xofluza tablet, bringing affordable single-dose flu treatment and prevention.

GSK and Spero Therapeutics’ newly approved carbapenem could be a standard of care in adults with complicated urinary tract infections who prefer oral administration.

How pharmacists differentiate respiratory diseases at the counter.

Phase 3 data show a once-weekly HIV pill maintains viral suppression like daily therapy, hinting at simpler long-acting care.

BA.3.2 variant spreads globally, testing vaccine matches as the FDA backs XFG immunizations.

Utah protocol streamlines large-volume immunoglobulin for measles-exposed infants as outbreaks surge.

Although currently contained outside of the US, the Bundibugyo strain of the virus reached an American worker in the Democratic Republic of Congo.

Oral ensitrelvir given within 72 hours cuts household symptomatic COVID-19 by 67%, showing safe postexposure prevention.